Heart failure drug study pulled before it even started
NCT ID NCT07221513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test the safety and tolerability of a new drug called JK07 in people with heart failure and a specific type of high blood pressure in the lungs. It planned to enroll about 20 to 30 adults aged 18 to 85. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP 2 PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Saint Francis Heart and Vascular Institute
Tulsa, Oklahoma, 74136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise as medicine: can a tailored workout program reduce hospital visits for heart failure patients?
- Heart failure care gets a Check-Up: study tests if sharing guidelines boosts treatment
- Tailored HIIT may boost fitness in stubborn heart failure
- Could eccentric exercise be the key to stronger hearts?
- AI-Powered patch could replace ultrasound for heart checkups
- New hope for heart patients: drug may cut death risk after valve surgery